NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said first-quarter revenues increased 5 percent as R&D spending rose 17 percent and profit fell 13 percent.
 
Total receipts for the three months ended March 31 increased to $322.5 million from $308.3 million year over year.
 
Revenue from the company’s Clinical Diagnostics segment increased nearly 11 percent to $177.6 million, while receipts from the Life Science division slipped 2 percent to $141.6 million.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.